KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Debt to Equity (2016 - 2025)

Gilead Sciences (GILD) has disclosed Debt to Equity for 17 consecutive years, with $1.27 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Debt to Equity fell 0.76% year-over-year to $1.27, compared with a TTM value of $1.27 through Jun 2025, down 0.76%, and an annual FY2024 reading of $1.39, up 26.36% over the prior year.
  • Debt to Equity was $1.27 for Q2 2025 at Gilead Sciences, down from $1.31 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.59 in Q1 2021 and bottomed at $1.1 in Q4 2023.
  • Average Debt to Equity over 5 years is $1.29, with a median of $1.27 recorded in 2025.
  • The sharpest move saw Debt to Equity dropped 26.46% in 2021, then rose 26.36% in 2024.
  • Year by year, Debt to Equity stood at $1.27 in 2021, then fell by 6.13% to $1.19 in 2022, then fell by 7.67% to $1.1 in 2023, then grew by 26.36% to $1.39 in 2024, then decreased by 8.25% to $1.27 in 2025.
  • Business Quant data shows Debt to Equity for GILD at $1.27 in Q2 2025, $1.31 in Q1 2025, and $1.39 in Q4 2024.